We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

ANI Pharmaceuticals Inc (ANIP) Common Stock USD0.0001

Sell:$58.22 Buy:$74.56 Change: $0.74 (1.12%)
NASDAQ:0.10%
Prices delayed by at least 15 minutes | Switch to live prices |
Sell:$58.22
Buy:$74.56
Change: $0.74 (1.12%)
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
Prices delayed by at least 15 minutes | Switch to live prices |
Sell:$58.22
Buy:$74.56
Change: $0.74 (1.12%)
Prices delayed by at least 15 minutes | Switch to live prices |
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

ANI Pharmaceuticals, Inc. is a diversified biopharmaceutical company, which serves patients in need by developing, manufacturing and marketing branded and generic prescription pharmaceutical products, including for diseases with high unmet medical need. Its three pharmaceutical manufacturing facilities, of which two are located in Baudette, Minnesota, and one is located in East Windsor, New Jersey, are together capable of producing oral solid dose products, as well as semi-solids, liquids and topicals, controlled substances, and potent products. The Company has a commercial portfolio of 116 products with a variety of indications and a robust portfolio of pipeline products. It has acquired the NDAs for and market Atacand, Atacand HCT, Arimidex, Casodex, Lithobid, Vancocin, Inderal LA, Inderal XL, InnoPran XL, Oxistat, Veregen, and Pandel. The Company sources the raw materials for its products from both domestic and international suppliers.

Contact details

Address:
210 Main Street West
BAUDETTE
56623
United States
Telephone:
+1 (218) 6343500
Website:
https://www.anipharmaceuticals.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
ANIP
ISIN:
US00182C1036
Market cap:
$1.39 billion
Shares in issue:
21.08 million
Sector:
Pharmaceuticals
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
NASDAQ Comb. Composite

Key personnel

  • Nikhil Lalwani
    President, Chief Executive Officer, Director
  • Stephen Carey
    Chief Financial Officer, Senior Vice President
  • Krista Davis
    Chief Human Resource Officer
  • Meredith Cook
    Senior Vice President, General Counsel, Company Secretary
  • Chad Gassert
    Senior Vice President - Corporate Development and Strategy
  • Ori Gutwerg
    Senior Vice President - Generics
  • James Marken
    Senior Vice President - Operations
  • Christopher Mutz
    Senior Vice President, Head of Rare Diseases
  • Muthusamy Shanmugam
    Director, Head of Research and Development, Chief Operating Officer - Novitium Operations

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now

Options

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.